Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Decreases By 36.7%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 44,297 shares, a decline of 36.7% from the November 30th total of 69,969 shares. Based on an average daily trading volume, of 68,762 shares, the short-interest ratio is presently 0.6 days. Approximately 2.3% of the company’s stock are short sold. Approximately 2.3% of the company’s stock are short sold. Based on an average daily trading volume, of 68,762 shares, the short-interest ratio is presently 0.6 days.

Alaunos Therapeutics Stock Performance

Shares of NASDAQ TCRT opened at $3.23 on Friday. Alaunos Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $6.20. The company has a market cap of $7.49 million, a PE ratio of -1.40 and a beta of -1.29. The business has a 50-day simple moving average of $3.26 and a two-hundred day simple moving average of $3.15.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.90) by $4.35.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Alaunos Therapeutics in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.